KEYNOTE-189 Final Data Release Stake in its Gorgeous Transformation Road

The KEYNOTE-189 study has received the attention of experts and scholars around the world since its publication, and has rapidly rewritten clinical practice to establish a first-line standard therapeutic status in The Paboli Zuma chemotherapy (Pemequer-platinum) in EGFR gene mutation negative and ALK negative non-small cell lung cancer (NSCLC)Here's a look back at the underlying KEYNOTE-189 from the appearance, to the amazing, to the gorgeous debut of the transformationThe KEYNOTE-189 study was a randomized, controlled, double-blind phase III clinical trial in which patients with advanced non-scale non-scale lung cancer with eGFR mutation negative or ALK negative were treated at the beginning of the treatment, randomly enrolled in the group at a 2:1 ratio to the Paboli synth-based combination-meme-seditus and platinum group (Paboli-Zhuzumab,1 time, 4 consecutive cycles of the drug), or the group of combined sepsis and pabosaFollow-up treatment can be maintained with pabolyzumab or placebo combined with permeitus for treatment until the end of 35 cyclesIf patients in the placebo combined chemotherapy group show edimen, cross-over to the Paboli zuma supretic chemotherapy group is allowed for treatmentThe final analysis results of the ASCO Conference, KEYNOTE-189 Research were announcedLas Palmas, spain, reported the final OS data from the KEYNOTE-189 studyThe results showed that the OS of Pemeressin combined with platinum drugs was 22.0 months, better than the OS of pure chemotherapy group of 10.6 months(Abstract: 9582) The study set PFS and OS as the joint primary research endpoint, ORR as the secondary research endpoint, and PFS2 as the exploratory endpointMedian follow-up time was 31.0 months, 84 patients crossed into the Paboli-Zhu monobresistance treatment group, and the median OS of the combined Paboli-Zhu monobresistance therapy was 22.0 months (95% CI 19.5-24.5 months), which was better than 10.6 months of simple chemotherapy (95% CI 8.7-13.6 months, HR.056, 95%CI.69.69)The two groups of PFS were 9.0 months (95% CI 8.1-10.4 months) and 4.9 months (95% CI 4.7-5.5 months, HR 0.49, 95% CI 0.41-0.59)The 2-year OS rate was 45.7% vs27.3%, the 2-year PFS rate was 22.0% vs3.4%, and the ORR was 48.3% vs.19.9%Fifty-six patients received a full 35-cycle treatment with an ORR of 85.7% and a median OS was not reachedIn 72.1% and 66.8% of patients, respectively, had adverse reactions of 3 degrees and aboveThe study showed that Paboli-Supremal-combined chemotherapy could provide patients with a sustained OS, PFS benefit and manageable safetyThe results supported Paboli zumas in combination chemotherapy as a first-line treatment in Patients with EGFR/ALK-negative, previously untreated metastatic non-scale NSCLCIn May 2017, based on the results of The Second Phase II KEYNOTE-021 clinical study, the FDA accelerated the approval of Paboli Singad-Combination Permequeleta-Carper for first-line treatment in EGFR/ALK-negative, previously untreated locally advanced or metastatic NSCLC patients, but the treatment was not widely used due to the lack of positive results from Phase III clinical studiesAt the Annual Meeting of the American Association for Cancer Research (AACR) in mid-April 2018, the results of the third issue of KEYNOTE-189 were first published and published online in the New England Journal of MedicineThe results showed that paboli-singyl-supres-platinum-and-platinum (experimental group) significantly extended patients' progression-free survival (PFS) and total survival (OS) compared to placebo s.peme-cocter (control group), regardless of PD-L1 expressionThis is an unprecedented therapeutic effect for EGFR/ALK-negative, previously untreated metastatic non-scaly NSCLC patients, and establishes the first-line standard treatment status of Paboli-Zhu-Zuma-combined pemeciqueplatin in this segment of patientsAt the 2019 AACR annual meeting, the underlying retrospective assessment analysis of the underlying liver or brain transfer patients at the KEYNOTE-189 baseline showed significant benefits to PFS and OS in patients regardless of whether the patient had combined liver metastasis or brain transfer at baseline(1) Baseline combined brain metastasis patients, the median OS of the Paboli Zuma anti-combination chemotherapy group was 19.2 months, the pure chemotherapy group was 7.5 months (HR.41, 95% CI 0.24 to 0.67), compared to simple chemotherapy, Paboli-Zuma-combined chemotherapy can significantly prolong the patient's total survival time, which is 2.5 times that of the traditional chemotherapy regimenNo progression survival analysis, paboli zuma suprecine combined chemotherapy group of 6.9 months, simple chemotherapy group for 4.7 months (HR,42, 95% CI 0.27 to 0.67), Paboli zumas combined chemotherapy can significantly prolong the patient's PFS, reduce the risk of death by 58% disease progression(2) Baseline unconsolidated brain metastasis patients, the median OS in the Paboli Zuma anti-combination chemotherapy group was 22.4 months, and the pure chemotherapy group was 12.1 months (HR.59, 95% CI 0.46 to 0.75), the median PFS was 9.2 months in the Paboli Zuma-Combined Chemotherapy Group and the placebo combined chemotherapy group was 4.9 months (HR-0.48, 95% CI 0.27 to 0.67)Paboli zumas combined chemotherapy significantly prolongs the patient's OS and PFS, regardless of whether the patient's baseline is combined with brain metastasis(3) Baseline combined liver metastasis patients, compared to simple chemotherapy, Paboli zuma suprecline chemotherapy extended by 6 months OS (12.6 months vs 6.6 months, HR 0.62, 95% CI 0.39 to 0.98)In terms of non-progression survival, the median PFS was 6.1 months in the Paboli-Zhuzumab-combined chemotherapy group and the pure chemotherapy group was 3.4 months (HR-0.52, 95% CI 0.34 to 0.81)(4) In patients with baseline uncombined liver metastasis, the oS was 23.7 months in the Paboli-Zuma-combined chemotherapy group and 13.2 months in the pure chemotherapy group (HR.58,95% CI 0.45 to 0.74)At the same time, Paboli zumas combined chemotherapy also extended the patient's PFS for 9.2 months, and the chemotherapy group alone was 5.4 months (HR.52, 95% CI 0.34 to 0.81)Paboli zumas combined chemotherapy significantly prolongs the patient's OS and PFS, regardless of whether the patient is combined with liver metastasis at baselineThe results showed that the first-line treatment of EGFR negative or ALK fusion negative advanced non-scale non-small cell lung cancer compared to placebo combined with pemequesega platinum, Paboli sing-singa," and whether or not the patient combined liver metastasis or brain metastasis at baseline, the OS and PFS of the patient could benefit significantly AT THE 2019 ASCO ANNUAL MEETING, THE FIRST DATA ON PFS2 AFTER THE KEYNOTE189 STUDY OF SECOND-LINE TREATMENT WERE PUBLISHED At the 2019 ASCO conference, the KEYNOTE-189 study updated the OS results after extended follow-up and reported the results of PFS2 for the first time The researchers collected data on anti-tumor treatment options and efficacy after first-line progression in two groups of patients, and PFS2 was defined as the time of progress or death after randomization to starting second-line treatment (1) After 18.7 months of median follow-up time, the Paboli Zuma anti-combination chemotherapy group still observed continuous OS (22.0 vs 10.7 months for both groups, HR 0.56, 95% CI 0.45 to 0.70; P 0.00001) and PFS benefit (mPFS in both groups 9.0 vs 4.9 months, HR 0.48, 95% CI 0.40 to 0.58; P 0.00001) The PFS and OS benefits of the Paboli zuma sein-combined chemotherapy group were observed regardless of the patient's PD-L1 TPS grouping (2) After the progress of first-line treatment, 44.6% and 59.2% of patients in the Paboli Zuma anti-combination chemotherapy group and the simple chemotherapy group received at least 1 line of treatment, of which 13.4% and 53.9% were patients who received the treatment of PD-1/L1 monobify, respectively (40.8% of patients in the cross-study group of the chemotherapy group) (3) PFS2 analysis showed that in the ITT population, PFS2 in the Paboli zuma anti-combination chemotherapy group was significantly higher than that of the pure chemotherapy group (the two groups of mPFS2 were 17.0 vs 9.0 months, HR 0.49, 95% CI 0.40 The PFS2 benefits of the Paboli zuma anti-combined chemotherapy group were observed regardless of the PD-L1 TPS grouping (TPS s 50%, 1 to 49% and 1% of the patients) It is worth noting that in patients with PD-L1 of 50% and PD-L1 at 1%, the two groups of PFS2 had similar HR values The paboli zuma seinameta combined chemotherapy group nearly doubled between the median OS, PFS and PFS2 compared to the simple chemotherapy group Extended follow-up observations that safety and tolerance are still manageable This study data further supports that Paboli-Zuma-combination chemotherapy should be recommended for late-stage non-scale NSCLC first-line therapy, regardless of the patient's PD-L1 expression level Current immunotherapy has changed the treatment pattern of driving gene-negative late-stage NSCLC, and in the first-line treatment of EGFR/ALK-negative non-scale NSCLC, there is no doubt that the KEYNOTE-189 study has led the way.